Egrifta (Tesamorelin) Geriatric (65+) Monitoring: A Complete Clinical Guide

What Is Tesamorelin and Why Do Older Adults Require Special Oversight?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete endogenous growth hormone (GH). The FDA approved Egrifta for reducing excess visceral adipose tissue (VAT) in HIV-infected adults with lipodystrophy in 2010, based largely on two phase 3 trials. In the landmark Falutz et al. study published in the New England Journal of Medicine, 412 HIV-infected adults received tesamorelin 2 mg daily or placebo for 26 weeks. The tesamorelin group achieved a 15.2% reduction in VAT versus a 4.8% increase in the placebo arm (P<0.001) [1].

Adults aged 65 and older represent a growing fraction of people living with HIV in the United States. The CDC estimated in 2021 that roughly 47% of Americans with HIV are aged 50 or older, a proportion that continues to rise as antiretroviral therapy extends life expectancy [2]. As this population ages, clinicians prescribing Egrifta must account for age-related physiology that the original registration trials did not fully capture: lower baseline GH secretion, reduced renal clearance, increased polypharmacy, higher baseline fall and fracture risk, and diminished glucose reserve.

The FDA prescribing information for Egrifta notes that clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects, and recommends "caution" in this population [3]. That single sentence places the burden of protocol design squarely on the prescribing clinician.

Baseline Assessment Before Starting Tesamorelin in a 65+ Patient

Before the first injection, a structured baseline workup reduces the chance of undetected contraindications and gives monitoring intervals a reference point to measure against.

Collect the following at baseline:

Metabolic panel. Fasting plasma glucose, HbA1c, fasting lipid panel, and comprehensive metabolic panel with liver enzymes. Tesamorelin transiently raises insulin-like growth factor 1 (IGF-1) and may worsen insulin resistance, particularly in older adults who already have impaired glucose tolerance [3]. A baseline HbA1c above 7.5% should prompt a discussion with the patient's endocrinologist or primary care provider before initiating therapy.

IGF-1 level (age- and sex-adjusted). IGF-1 naturally declines with age. Starting treatment when IGF-1 is already at the lower end of normal, and then normalizing it, carries different risk than overshooting into a supraphysiologic range. The Endocrine Society recommends maintaining IGF-1 within the age-adjusted reference range during GH-axis therapies [4].

Renal function (eGFR and serum creatinine). Age-related nephron loss reduces GFR by roughly 0.75 mL/min/1.73 m² per year after age 40, meaning a healthy 70-year-old may have an eGFR of 55 to 65 mL/min/1.73 m² without any underlying kidney disease [5]. No formal dose-adjustment data exist for tesamorelin in severe renal impairment; patients with eGFR <30 mL/min/1.73 m² should be flagged for case-by-case review.

Falls and fracture risk screening. Administer the Timed Up and Go (TUG) test and review bone mineral density (DEXA) data if available. GH-axis stimulation promotes fluid retention, which may cause transient peripheral edema and increase fall risk, especially in a patient already on antihypertensives or diuretics.

Polypharmacy review. Tesamorelin may transiently suppress cortisol response to stimulation and may alter the peripheral conversion of T4 to T3 [3]. Patients on corticosteroids, thyroid hormone replacement, or insulin may need dose adjustments after tesamorelin initiation.

Thyroid function. TSH and free T4 at baseline. Growth hormone stimulates deiodinase activity, shifting thyroxine metabolism toward active T3. In older adults with subclinical hypothyroidism already on levothyroxine, this shift can produce symptoms of relative over-replacement [3].

IGF-1 Monitoring: The Central Safety Signal in Older Adults

IGF-1 is the primary biomarker used to titrate and monitor growth-hormone-axis therapies. In adults aged 65 and older, IGF-1 reference ranges are considerably lower than in younger adults, which means a level that appears "normal" for a 35-year-old represents supraphysiologic stimulation in a 70-year-old.

Check IGF-1 at 6 weeks after initiation to confirm the patient is responding and that levels have not exceeded the upper limit of the age-adjusted range. Repeat at 6-month intervals thereafter. If IGF-1 exceeds the upper limit of the age-appropriate reference range on two consecutive measurements, the prescribing clinician should reduce frequency of administration (for example, every-other-day dosing) or discontinue the drug entirely.

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states: "We recommend monitoring serum IGF-1 levels every 6 months during dose titration and annually once a stable dose is reached, with the goal of maintaining IGF-1 in the age- and sex-adjusted normal range" [4]. Although that guideline addresses GH deficiency rather than HIV lipodystrophy specifically, the physiologic rationale for IGF-1 monitoring transfers directly to tesamorelin use.

The HealthRX Geriatric Tesamorelin Monitoring Framework structures IGF-1 checks as follows: baseline, week 6, month 6, month 12, then annually if stable. Any value exceeding the 97.5th percentile for age and sex triggers a clinical review within 4 weeks rather than waiting for the next scheduled appointment.

Glucose and Metabolic Monitoring

Older adults on antiretroviral therapy already carry an elevated baseline risk of insulin resistance from both HIV itself and from nucleoside reverse transcriptase inhibitors and protease inhibitors [6]. Adding tesamorelin, which raises GH and IGF-1, introduces an additional counter-regulatory pressure on glucose homeostasis.

In the Falutz et al. extension study, HbA1c increased by a mean of 0.12% in the tesamorelin group over 52 weeks, a small but statistically detectable shift [1]. In older adults with pre-diabetes (HbA1c 5.7 to 6.4%), that increment may be enough to cross the diagnostic threshold for type 2 diabetes.

Monitor fasting plasma glucose and HbA1c at baseline, at 3 months after initiation, and then every 6 months. Patients with baseline HbA1c of 5.7% or higher warrant monthly fasting glucose checks during the first 3 months. Any patient who develops confirmed diabetes while on tesamorelin should have a frank discussion about the benefit-to-risk ratio of continuing therapy.

Lipid monitoring follows a similar schedule. VAT reduction generally improves triglycerides and HDL cholesterol, which is one of the rationale points for prescribing in the first place. Confirm that the expected lipid benefit is materializing by checking a fasting lipid panel at 6 months and annually thereafter.

Renal Function and Fluid Balance in the Geriatric Patient

Tesamorelin promotes sodium and water retention through GH-mediated effects on the renal tubule. In younger adults, this typically manifests as mild peripheral edema. In older adults, whose baseline renal reserve is reduced and who are more likely to be on antihypertensives, diuretics, or nonsteroidal anti-inflammatory drugs, fluid retention can precipitate or worsen hypertension, heart failure, or electrolyte imbalances.

Check serum creatinine, BUN, and electrolytes (sodium, potassium) at baseline, at month 3, and every 6 months. Monitor body weight at each clinic visit; a rapid gain of more than 2 kg over 2 to 4 weeks without a dietary explanation warrants an early renal and cardiac review.

For patients with eGFR <60 mL/min/1.73 m² at baseline, shorten the monitoring interval to every 3 months for the first year. No pharmacokinetic data support a formal dose reduction in mild-to-moderate renal impairment, but heightened surveillance is the pragmatic minimum standard.

The AACE position statement on growth hormone therapies in special populations notes that volume expansion in older patients can produce clinically significant hemodynamic changes that are silent in younger cohorts [7]. Leg edema, new-onset dyspnea, and orthostatic hypotension are early signals that require prompt evaluation.

Falls, Fractures, and Musculoskeletal Safety

Fluid retention from tesamorelin may produce carpal tunnel syndrome, joint pain (arthralgia), and myalgia. These adverse effects are well-documented in the Egrifta prescribing label and appear more frequently in patients aged 65 and older, likely because pre-existing osteoarthritis and reduced tissue compliance amplify the discomfort [3]. Arthralgia and myalgia were reported in approximately 6.1% and 5.6% of tesamorelin-treated patients in clinical trials, compared with 2.8% and 2.3% on placebo.

More pressing in the geriatric setting is whether peripheral edema, joint pain, or altered body composition shifts the patient's fall risk profile. Growth hormone administration increases lean body mass and may improve muscle strength over 6 to 12 months of treatment, a potential benefit. But in the early weeks, edema and joint discomfort may transiently worsen mobility.

Administer the Timed Up and Go test at baseline and at 6 months. For patients who score above 12 seconds on TUG at baseline, a physical therapy referral before or alongside tesamorelin initiation is reasonable. Review current medications for fall risk contributors, including benzodiazepines, anticholinergics, alpha-blockers, and opioids, at every visit.

DEXA scanning for bone mineral density is not required solely because a patient is starting tesamorelin, but if a scan has not been performed in the prior 2 years, obtaining one at baseline provides useful longitudinal data given the intersection of aging, HIV, antiretroviral therapy, and GH-axis changes on bone health [8].

Drug Interaction Review in Polypharmacy-Heavy Patients

Adults aged 65 and older average five or more prescription medications [9]. Tesamorelin introduces three pharmacodynamic interaction categories that deserve attention at every prescription review.

Corticosteroids. GH stimulation modestly increases cortisol clearance by inducing 11-beta-hydroxysteroid dehydrogenase. Patients on physiologic or pharmacologic steroid doses (for example, hydrocortisone for adrenal insufficiency) may experience relative adrenal under-replacement. Review cortisol replacement doses at month 3 and after any significant dose change to tesamorelin [3].

Thyroid hormone. As noted above, increased deiodinase activity under GH stimulation can shift T4-to-T3 conversion, producing relative over-replacement in patients on stable levothyroxine. Check TSH and free T4 at month 3 after initiation, particularly if the patient reports palpitations, heat intolerance, or unexplained weight loss.

Insulin and oral hypoglycemics. Rising IGF-1 and GH levels may blunt insulin sensitivity. Patients on insulin secretagogues (sulfonylureas) or insulin itself may need upward dose adjustment. Conversely, if tesamorelin is discontinued, their hypoglycemic agents may become relatively more potent, risking hypoglycemia. Alert patients and their diabetes care team before starting or stopping tesamorelin.

Antiretroviral interactions. Tesamorelin is not metabolized by CYP450 enzymes, so pharmacokinetic interactions with ritonavir-boosted regimens are not expected. Nonetheless, protease inhibitors and some integrase inhibitors alter lipid and glucose metabolism independently; separating their contribution from tesamorelin's effects at monitoring visits requires good clinical judgment [6].

The 26-Week Decision Point: Reassessing Continuation

The Egrifta prescribing information specifies that the primary endpoint in clinical trials was at 26 weeks [3]. If a patient has not achieved a clinically meaningful reduction in waist circumference or VAT (typically defined as at least a 1 to 1.5 cm decrease in waist circumference), continued use is difficult to justify on efficacy grounds.

In an older adult, the 26-week reassessment is also an opportunity to weigh the cumulative safety experience. Has glucose control worsened? Has the patient had falls? Has edema required diuretic initiation? These findings shift the benefit-to-risk calculus toward discontinuation.

Stopping tesamorelin leads to VAT reaccumulation within 12 months of discontinuation, as demonstrated in the Falutz et al. extension data [1]. Framing this reality clearly for the patient at the outset helps set realistic expectations and avoids the perception that stopping represents "failure."

Endocrine Axis Interactions Specific to Aging

Older adults have reduced hypothalamic pulsatility and a blunted GH response to GHRH. This is relevant for two reasons. First, the drug's efficacy may be attenuated in very old patients (80+) because the remaining somatotroph reserve is lower. Second, the pituitary response to exogenous GHRH stimulation remains present but may be less predictable, meaning IGF-1 responses are more variable in geriatric patients than in the 40-to-60-year-old cohort that dominated the trial population.

Thyroid and adrenal axis changes in aging further complicate interpretation of monitoring data. Subclinical hypothyroidism is present in roughly 10 to 15% of adults aged 65 and older [10]. Initiating tesamorelin in a patient with undetected subclinical hypothyroidism may unmask symptoms by increasing T3 demand, making pre-treatment TSH screening non-negotiable.

Deprescribing Considerations and Exit Strategy

No formal deprescribing guideline exists specifically for tesamorelin in older adults, but standard geriatric pharmacotherapy principles apply. Reassess at 26 weeks, 52 weeks, and annually thereafter. Consider discontinuation if any of the following apply:

• IGF-1 persistently above age-adjusted upper limit of normal despite dose modification
• New or worsening diabetes mellitus (HbA1c above 8.0% despite optimized antidiabetic therapy)
• Symptomatic edema requiring new diuretic therapy
• Two or more falls in a 6-month period potentially attributable to edema or arthralgia
• Malignancy diagnosis (GH-axis stimulation is contraindicated with active malignancy) [3]
• eGFR decline of more than 30% from baseline over 12 months without an identified reversible cause
• Patient preference after informed discussion of benefit-to-risk ratio

When stopping, taper is not required because tesamorelin acts on the GHRH receptor and does not suppress the pituitary axis in a manner requiring stepwise withdrawal. However, monitoring glucose and thyroid function at 6 weeks after discontinuation catches any counter-regulatory rebound, particularly in patients on insulin or levothyroxine.

Practical Monitoring Schedule Summary

The table below consolidates the monitoring parameters into a timeline appropriate for a 65+ patient on Egrifta.

| Parameter | Baseline | Week 6 | Month 3 | Month 6 | Month 12 | Annual | |---|---|---|---|---|---|---| | IGF-1 (age-adjusted) | Yes | Yes | | Yes | Yes | Yes | | Fasting glucose | Yes | | Yes | Yes | Yes | Yes | | HbA1c | Yes | | Yes | Yes | Yes | Yes | | Fasting lipids | Yes | | | Yes | Yes | Yes | | eGFR / creatinine | Yes | | Yes | Yes | Yes | Yes | | Electrolytes | Yes | | Yes | Yes | Yes | Yes | | TSH / free T4 | Yes | | Yes | | Yes | Yes | | Body weight | Yes | Yes | Yes | Yes | Yes | Yes | | Timed Up and Go | Yes | | | Yes | Yes | Yes | | Polypharmacy review | Yes | | Yes | Yes | Yes | Yes | | Waist circumference / VAT assessment | Yes | | | Yes | Yes | Yes |

For patients with eGFR <60 mL/min/1.73 m² at baseline, move the month-3 renal panel to month 1 and repeat at month 3 and every 3 months for the first year.

Patient Education Points for Older Adults on Tesamorelin

Older patients and their caregivers benefit from concrete, specific instructions rather than general guidance. Cover the following at the initiation visit and again at month 3:

Injection site technique. Subcutaneous injection into the abdomen, rotating among four quadrants. Lipodystrophy itself may alter subcutaneous tissue quality; confirm absorption is adequate by checking IGF-1 response at week 6.

Edema recognition. Explain that ankle and leg swelling in the first 4 to 8 weeks is a known side effect. Instruct patients to call if swelling reaches the knee or if they develop shortness of breath.

Glucose symptoms. Patients with pre-diabetes should know the symptoms of hyperglycemia (polyuria, polydipsia, fatigue) and have a clear threshold for calling the clinic.

Joint pain management. Mild arthralgia may respond to dose-timing adjustments or acetaminophen. Avoid NSAIDs in patients with eGFR <60 mL/min/1.73 m² or on concurrent anticoagulation.

Storage. Egrifta requires reconstitution before injection. Older adults living alone or with cognitive impairment may need caregiver support for daily preparation.